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Abstract 
The high resolution, accurate mass and fast scanning features of the OrbitrapTM mass 
spectrometer, combined with the separation power of ultrahigh performance liquid 
chromatography were applied for the first time to study the metabolic profiles of several 
organic flame retardants (FRs) present in indoor dust. To mimic real-life exposure, in 
vitro cultured human hepatocytes were exposed simultaneously to various FRs in an 
indoor dust extract for 24 hours. Target parent FRs, hexabromocyclododecanes (α-, β- 
and γ-HBCDs), tris-2-chloroethyl phosphate (TCEP), tris (1-chloro-2-propyl) phosphate 
(TCIPP) and tris (1,3-dichloro-2-propyl) phosphate (TDCIPP), were separated in a 
single run for the first time using alternating positive and negative heated ESI source. 
Further metabolite separation and identification was achieved using full scan (70,000 
FWHM), accurate mass (up to 1 ppm) spectrometry. Structural confirmation was 
performed via all ion fragmentation (AIF) spectra using the optional higher collisional 
dissociation (HCD) cell and MS/MS analysis. First insights into human metabolism of 
HBCDs revealed several hydroxylated and debrominated phase I metabolites, in 
addition to conjugated phase II glucuronides. Furthermore, various hydroxylated, 
oxidized and conjugated metabolites of chlorinated phosphorous FRs were identified, 
leading to the suggestion of α-oxidation as a significant metabolic pathway for these 
compounds. 
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1 Introduction 
Cellular stress is a general term covering a wide range of molecular changes that cells 
undergo in response to various stressors. Environmental stressors may include 
extremes of temperature, mechanical damage and exposure to toxins or xenobiotics 
(e.g. flame retardant chemicals (FRs)).1 Several studies have highlighted the importance 
of indoor dust as a pathway of human exposure to FRs and related persistent organic 
pollutants (POPs).2,3 However, few studies have investigated the metabolic pathways of 
FRs present in indoor dust. Most of these studies have focused on metabolism of 
polybrominated diphenyl ethers (PBDEs) using animal or human liver microsomes,4 
hepatic S9 fractions5 and rarely, human hepatocytes.6 Furthermore, the restrictions on 
production and usage of PBDEs followed by inclusion of the Penta- and Octa-BDE 
commercial formulations as persistent organic pollutants (POPs) under Annex A of the 
UNEP Stockholm Convention on POPs7 have led to the application of alternative FRs to 
meet fire safety regulations. Currently, very little is known about the metabolic 
pathways of alternative FRs in humans. Among these alternatives, the chlorinated alkyl 
phosphates: tris-2-chloroethyl phosphate (TCEP), tris (1-chloro-2-propyl) phosphate 
(TCIPP) and tris (1,3-dichloro-2-propyl) phosphate (TDCIPP), in addition to 
hexabromocyclododecane (HBCD); are associated with a variety of applications in a 
wide range of consumer products.  
TCEP, TCIPP and TDCIPP have been widely applied as FRs in polyurethane foam for 
domestic, public, and automotive applications with an estimated annual consumption of  
91,000 tonnes in 2006.8 Each were subject to an EU risk assessment process under an 
Existing Substances Regulation (EEC 793/93). As a result, all 3 compounds were 
classified as persistent organic compounds in the aquatic environment and reported to 
fulfil PBT criteria.9 In addition, several studies have reported them to display adverse 
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effects including reproductive toxicity and carcinogenic effects on lab animals.8 Hence, 
TCEP is classified by the EU as a “potential human carcinogen”,10 while TDCIPP is 
classified under regulation EC 1272/2008 as a category 2 carcinogen with hazard 
statement H351 “suspected of causing cancer”.11 Information on the biotransformation 
pathways of organophosphate flame retardants (PFRs) is limited. While phosphoric acid 
diesters were the major metabolites of TDCIPP and TCEP identified in rat urine,12 a 
recent in vitro study using human liver microsomes and S9 fractions reported the 
replacement of Cl with OH followed by conjugation as a major metabolic pathway for 
TCEP and TCIPP.13    
HBCD is an additive FR widely applied in expanded and extruded polystyrene foams 
(EPS/XPS) used for thermal insulation of buildings and to a lesser extent in the 
backcoating of fabrics and high impact polystyrene casing for electrical goods. The 
commercial formulations consist mainly of α-, β-, and γ-diastereomers with γ- 
predominant (>70% ΣHBCD). HBCD has low water solubility (49, 15, and 2 µg L-1 for α-, 
β-, and γ-HBCD respectively), a fairly low vapor pressure (6.27 x 10-5 Pa) and is 
persistent. It can therefore bioaccumulate and undergo long-range transport.14 Oral 
exposure to HBCDs was reported to induce hepatic cytochrome P450 enzymes and alter 
the normal uptake of neurotransmitters in rat brain. It can cause disruption of thyroid 
function, the reproductive system, nerve function and development in various classes of 
vertebrates.15 Therefore, HBCD was recently included in Annex A of the Stockholm 
Convention on POPs with an exemption for use in EPS/XPS in buildings.7 Currently, little 
is known about the metabolism of HBCDs in humans or other biota. Recent in vitro 
studies in rat and trout liver S9 fractions showed oxidation (hydroxylation) and 
reductive debromination as the main biotransformation pathways,16 which was in 
agreement with in vivo studies in Wistar rats17 and female mice.18 To the authors’ 
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knowledge, there exists hitherto, no studies of HBCD metabolism in human liver 
preparations. Moreover, there are no studies on the biotransformation of HBCDs, TCEP, 
TCIPP, and TDCIPP in indoor dust by human hepatocytes which contain the full system 
for Phase I and Phase II metabolic reactions. Furthermore, very little is known about the 
metabolic behavior of human liver cells upon concomitant exposure to multiple 
stressors which mimic the real life situation. Biotransformation of FRs can be a major 
determinant of the toxicological and bioaccumulative properties of these xenobiotics in 
humans.  
Although targeted routine analysis of HBCD diastereomers and chlorinated alkyl 
phosphates using various LC-MS and GC-MS techniques is well-documented,8,15 
separation and identification of metabolites following exposure of human hepatocytes 
to a complex mixture of the target FRs requires use of high resolution mass 
spectrometric methods (HR-MS). While the application of time-of-flight (TOF-MS) 
coupled to HPLC to study the in vitro biotransformation of individual chlorinated alkyl 
phosphates has been recently reported;13 the ability of ultra high mass resolution mass 
spectrometric methods like Orbitrap-MS to inform understanding of human metabolism 
of FRs has not yet been evaluated. The mass resolution of Orbitrap-MS (up to 140,000 
full width at half maximum (FWHM)) and mass accuracy (up to 1 ppm), provides 
accurate mass measurements facilitating resolution of target analytes from background 
matrix interferences and isobaric compounds. Such capacity to obtain mass spectra with 
high mass accuracy at sufficient mass resolution and scan rates, opens substantial 
opportunities for combining targeted analysis with unbiased metabolite profiling which 
can provide new perspectives in metabolite analysis.19 Review of the available literature 
on in vitro metabolism of FRs present in indoor dust shows that studies were carried 
out via exposure of the metabolising system (i.e. liver microsomes, liver S9 fractions, 
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hepatocytes and/or liver slices) to a single contaminant or a small group of closely 
related contaminants (e.g. HBCDs).16,20 This simplified approach may allow for the 
detection and identification of the small number of metabolites formed using the most 
commonly available low/medium resolution MS or MS/MS systems. However, this 
might not closely reflect the in vivo situation where the metabolising system is 
simultaneously exposed to a wide range of various xenobiotics, which may greatly 
influence both the activity (e.g. induction or suppression) of the enzymes and the nature 
of the produced metabolites (i.e. presence of preferential substrates for certain enzyme 
groups). Nevertheless, separation and identification of the complex metabolites mixture 
resulting from simultaneous exposure of hepatocytes to a wide range of contaminants 
present in indoor dust, needs a combination of high performance chromatographic 
separation and ultra high resolution mass spectrometry.     
Against this backdrop, the aim of the current work was to study for the first time the 
metabolic profiles of HBCDs, TCEP, TCIPP and TDCIPP in indoor dust applied 
concomitantly to human hepatocyte cultures using UPLC-OrbitrapTM-MS.   
 
2 Experimental 
2.1 Chemicals and reagents 
All chemicals were HPLC grade obtained from Sigma-Aldrich Chemical Company (UK) 
unless otherwise stated. 
2.2 Cell culture 
Human HepG2/C3A cells were generously provided by Prof. Ronny Blust from the 
University of Antwerp, Belgium. HepG2/C3A cells were cultured in William’s E 
medium(Sigma, UK) supplemented with 5% heat-inactivated fetal bovine serum (FBS) 
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(APP, Germany), 100 U penicillin/mL and 100 μg streptomycin/mL (APP, Germany), 
4µM L-glutamine (APP, Germany) and 0.4 µM sodium pyruvate (Sigma, UK) and 
incubated in 37°C with humidified air containing 5% CO2. Cells were digested with 
0.25% trypsin-EDTA and sub-cultured at 80% to 90% confluence exponentially growing 
HepG2/C3A cells were used for all assays.  
The potential cytotoxicity of HBCD to HepG2/C3A cells was evaluated by the CCK-8 
assay using a commercial kit, according to the manufacturers’ instruction (Dojindo 
Laboratories, Kumamoto, Japan). 
2.3 Dosing solutions 
The dosing solutions for this study were prepared to mimic real-life exposure of a 12.3 
kg toddler to indoor dust assuming a high dust ingestion scenario (200 mg dust day-1).21 
We used standard NIST SRM 2585 dust with known indicative values for all target 
compounds (Table SI-1). 240 mg of NIST SRM 2585 dust were extracted using 
pressurized liquid extraction (Dionex ASE 350, Sunnyvale, CA, USA) according to a 
previously reported method.22 The extract was concentrated under a gentle stream of 
nitrogent, followed by solvent exchange to 2 mL of DMSO using 500 µL of toluene as a 
“keeper” to minimize analyte loss (D1). Another dosing solution (D2) containing 100 
times the concentrations of target analytes in D1 was prepared by appropriate dilution 
of α-HBCD, β-HBCD, γ-HBCD, TCEP, TCIPP, and TDCIPP reference standards (Wellington 
Laboratories Inc., ON, Canada) with DMSO. D2 was used to mimic episodic high dose 
exposure which can be several orders of magnitude higher than average exposure 
scenarios. 23  
2.4 Human hepatocytes exposure experiments    
HepG2/C3A cells were seeded into 6 well plates at density of 106 cells in 2 mL culture 
media per well. After 24 hours acclimatization, cells were exposed to D1 or D2 (10 µL in 
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DMSO added into 2 mL media) and incubated at 37°C with humidified air containing 5% 
CO2. DMSO (10 µL) as vehicle was added into the same volume media as a control, while 
10 µL of D1 or D2 were also incubated alone with the culture media on the well plates 
adjacent to the hepatocytes and analyzed at the end of exposure to determine “real” 
exposure concentrations for QA/QC purposes (the final concentration of DMSO was 
0.5% (v/v) in all treatments). All experiments were performed in triplicate. After 24 
hours exposure, cells were harvested and kept frozen at -80°C until analysis.  
2.5 Sample extraction 
Samples were spiked with 2 mL of methanol and extracted by vortexing for 60 seconds, 
followed by ultrasonication for 5 minutes and centrifugation at 4,000 g for 3 minutes. 
This extraction cycle was repeated twice before the combined methanol extracts were 
reduced under a gentle stream of N2 to 150 µL in a HPLC vial.  
2.6 Instrumental Analysis  
Chromatographic analysis was achieved using a dual pump Ultimate 3000TM 
(ThermoScientific, Bremen, Germany) UHPLC system equipped with an Ultimate 
3000TM XRS autosampler. Analyte separation was achieved on an AccucoreTM RP-MS 
column (100 x 2.1 cm, 2.6 µm, ThermoScientific, Bremen, Germany) using a mobile 
phase of 1 mM ammonium acetate (mobile phase A) and Methanol (mobile phase B), 
each modified with 0.1% formic acid. The elution programme commenced with 25% B 
ramped up to 50% B over 0.5 min, then increased linearly to 100% B over 6 minutes. 
This was held for 4 minutes, then decreased to 50% B over 0.5 min and kept at this 
composition (to equilibriate the column) for a further 1 minute. Overall analysis time 
was 12 minutes using a constant flow rate of 0.18 mL min-1. The injection volume was 
10 μL and the column maintained at 37 °C throughout.  
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Identification of target analytes (HBCDs, TCEP, TCIPP and TDCIPP) and their 
metabolites was performed using an ExactiveTM Plus OrbitrapTM mass spectrometer 
(Thermo Scientific, Bremen, Germany) using an ESI source operated in both positive 
and negative ionization modes.  
Due to the lack of reference standards, high resolution full scan mass spectra were used 
to identify metabolites. Based on the chemical structures of individual studied 
substrates and the enzyme families (phase I and II metabolism) present in human 
hepatocytes, a  database containing the molecular structures of all theoretically possible 
metabolites was prepared and saved in TraceFinderTM software. Three successive filters 
were set in the software for initial metabolite identification: 
i. The peak signal to noise ratio (S/N) must exceed 10:1. 
ii. The m/z value of the molecular ion peak must be within 10 ppm of its theoretical 
value. 
iii. The Br or Cl isotope pattern must match within 5 % of the theoretically predicted 
abundances. 
The identity of potential metabolites were confirmed via all ion fragmentation (AIF) 
using the higher collisional dissociation (HCD) cell. Thermo XcaliburTM and 
TraceFinderTM 3.0 software was used for raw data interpretation and for 
targeting/identification of metabolites. The fragmentation patterns obtained from each 
metabolite provided additional information for structural elucidation. Further 
confirmation of metabolite structures were achieved via MS/MS analysis using the 
parent (nominal) mass from the Orbitrap full scan and the most predominant fragment 
obtained from the AIF analysis. Confirmatory tandem mass analyses were performed 
using a AB Sciex API 2000TM triple quadrupole mass spectrometer equipped with a 
TurboIonSpray® source used in the multiple reaction monitoring (MRM) mode. Source 
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and compound specific parameters were adjusted for each parent compound (i.e. 
HBCDs, TCEP, TCIPP and TDCIPP) via direct infusion experiments (2 ng µL-1 standard 
solution each, in methanol) using a built-in Harvard syringe pump at a flow rate of 10 µL 
min-1 (Table SI-2).   
3 Results and discussion 
3.1 Optimization of instrumental parameters 
Due to the lack of reference standards for metabolites of the target compounds, 
instrumental parameters were initially optimized using standard solutions of the parent 
analytes. While several studies exist for the analysis of HBCDs,15 with fewer reporting 
the analysis of chlorinated alkyl phosphates using LC/MS based techniques.8; this is the 
first study to attempt separation and identification of all target compounds within the 
same run. Several mobile phase gradients with different proportions of water, 
acetonitrile and methanol were tested, with various percentages of different additives 
including formic acid, ammonium acetate and ammonium chloride. While inclusion of 
acetonitrile in the mobile phase enhanced the resolution between β- and  γ-HBCDs, it 
was not essential for baseline separation and caused a general decrease in the ESI signal 
intensity for all target analytes. Therefore, acetonitrile was removed from the mobile 
phase and baseline separation of all target compounds within a reasonable run time (12 
min) was achieved using the mobile phase program described under section 2.6 (Figure 
1).  
Several C18-RP columns (100 x 2.1 cm) with different particle sizes, namely: SyncronisTM 
(1.7 µm), Hypersil goldTM (1.9 µm), AcclaimTM (2.2 µm), HypersilTM (2.4 µm) and 
AccucoreTM (2.6 µm) were tested for separation of the studied compounds. While all the 
tested columns provided baseline separation, better resolution factors with reasonable 
retention of the target analytes within acceptable pressure range, was achieved using 
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the AccucoreTM column (Figure 1). Columns with smaller stationary phase particle size 
required very high pressures - accompanied by  higher column temperatures - 
throughout the run, with potential for solvent leaks or emergency termination of the 
run should the pressure limit be exceeded. 
Following chromatographic separation, the analytes were introduced to the Orbitrap-
MS via a heated electrospray ionization (HESI) source with fast polarity switching 
between positive (PFRs) and negative (HBCDs) ionization modes. Optimised ESI source 
parameters are provided in table 1. The ions were then guided via a complex optical 
system to the C-trap which allows storage of a significant ion population prior to quick 
injection into the Orbitrap analyzer in short pulses, so that each mass-to-charge (m/z) 
population forms a sub-microsecond pulse. In this study, the automated gain control 
(AGC) was set to 3 x 106 ions for full scan analysis and 1 x106 ions for semi-quantitative 
analysis. The Orbitrap-MS can provide high mass accuracy (typically less than 3 ppm) 
with high resolution. While the maximum mass resolution of the Orbitrap-MS is 140,000 
FWHM,  this resulted in highly deformed peaks and a long scan time. Therefore, a mass 
resolution of 70,000 FWHM was selected for full scan analysis while a mass of  35,000 
FWHM was used for semi-quantitative analysis. Due to the lack of reference standards 
for putative Phase-I and Phase-II metabolites of the target compounds, identification of 
metabolites was based on their accurate mass provided by: a full MS scan, their 
fragmentation pattern obtained using the optional high energy collisional dissociation 
(HCD) cell, isotope patterns which reflect the presence of naturally occurring heavier 
isotopes of common atom (e.g. 81Br or 37Cl) (Figure SI-1), and confirmational MS/MS 
analysis (Table SI-2).  
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3.2 HBCD metabolic profile 
Following incubation of α-, β- and γ- HBCDs (present in a SRM2585 dust extract) with 
human hepatocytes, 2 peaks for pentabromocyclododecene (PBCD) and 1 peak for 
tetrabromocyclododecadiene (TBCD) were observed. The metabolites were identified 
and linked to their parent compounds based on: the acquired accurate mass spectra 
(Figure 2), AIF fragmentation pattern, retention time windows (on the basis that peaks 
of the lower brominated compounds will appear before the less polar parent 
compound) and LC-ESI-MS/MS analysis using the respective MRM for each metabolite 
(table SI-2). While this study is the first to report on HBCD metabolism in human 
models; PBCDs and TBCDs metabolites were previously reported in rat17 and mice18 in 
vivo studies. Moreover, we have recently reported on the formation of 3 PBCDs and 2 
TBCDs following incubation of  α-, β- and γ- HBCDs with rat S9 fractions.16 The 
debrominated metabolites have also been identified in human milk samples from UK24 
and USA25.  
As a result of phase I metabolism, several hydroxylation products of HBCDs, PBCDs and 
TBCDs were identified with a major ion cluster at [M+16]¯ and a predominant fragment 
at m/z = 80.9153 corresponding to the Br¯ ion (Figure 2). One di-hydroxylated and five 
mono-hydroxylated metabolites were identified for parent HBCDs; two mono-hydroxyl 
metabolites were identified for PBCDs and one mono-hydroxyl metabolite for TBCD 
(Table 2). Previous in vitro studies have reported several hydroxylated metabolites of 
HBCDs and its debrominated metabolites using induced rat liver microsomes26 and S9 
fractions.16 Brandsma et al. identified mono-hydroxyl metabolites of both PBCD and 
TBCD in male Wistar rats17. Another in vivo metabolic study in female mice detected 
both mono- and di- hydroxyl metabolites of PBCD but no hydroxyl TBCD derivatives18. 
Theoretically, the 6 main HBCD enantiomers can produce 48 possible allylic PBCD 
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structures and each HBCD enantiomer can lead to a maximum of six different 
diastereomeric mono- hydroxyl HBCD structures which can result in a huge number of 
possible di-hydroxyl HBCDs.26 Therefore, while the different number of metabolites 
identified in various studies may be attributed to species-specific variability in phase I 
metabolism and different exposure conditions,16, co-elution of one or more HBCD 
metabolites cannot be excluded in the absence of reference standards for these 
compounds. Collectively, these results support our previous findings that while 
cytochrome P450 enzymes are involved in the stereoselective phase I oxidative 
metabolism of HBCDs; the detection of penta- and tetra- brominated metabolites 
together with their hydroxylated products indicate sequential reductive debromination 
(not catalysed by cytochrome P450 enzymes27) as a potential pathway of HBCD 
metabolism. Despite mounting evidence of the involvement of deiodinase enzymes in 
the metabolic debromination of PBDEs28,29, further research is required prior to 
comparing these studies to HBCDs, due to the aliphatic nature of HBCDs as opposed to 
the aromatic structure of PBDEs. 
As a result of phase II metabolism, glucuronide conjugates were identified for the first 
time for both HBCDs and PBCDs at [M+176]¯. Glucuronide formation was identified via 
accurate MS spectra and matching isotope fractions (Figure 3). Conformatory AIF MS2 
spectra showed characteristic glucuronide fragments at m/z = 176 and 11330 (Figure SI-
2), which were used for confirmatory MS/MS analysis of the formed conjugates. An in 
vivo study identified a methylmercapturate conjugate of TBCD in the urine of female 
mice exposed orally to γ-HBCD.18 However, no mercapturate or sulfate conjugates could 
be identified in this study which may indicate species-specific differences in HBCD 
metabolism. To the author’s knowledge, this is the first study of HBCD metabolism in 
humans, which precludes comparison of results within the same species.  
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3.3 TCEP metabolic profile 
Several TCEP metabolites were identified using accurate MS spectra and confirmatory 
Cl isotope fractions (Figure 4). Based on relative peak area to the parent compound, 
bis(2-chloroethyl) hydrogen phosphate (BCEP) (Table SI-3) appeared the major 
metabolite formed by the studied human cell lines. This is in agreement with previous in 
vivo metabolic studies in rats and mice,31 and a previous in vitro study using human and 
rat liver preparations.32 In addition, a hydroxylated metabolite, bis(2-chloroethyl) 2-
hydroxyethyl phosphate (TCEP-M1), and its oxidation product, bis(2-chloroethyl) 
carboxymethyl phosphate (TCEP-M2), were positively identified (Figure 4 and Table SI-
3). TCEP-M1 was previously identified as a major TCEP metabolite following incubation 
with human liver microsomes,13 While TCEP-M2 was found in rat urine exposed to 
TCEP via gavage.31 Therefore, we hypothesize α-oxidation as a significant metabolic 
pathway of TCEP in human hepatocytes (Figure 5). The reaction starts with α-
hydroxylation of a terminal chloromethyl group resulting in an unstable chlorohydrin 
intermediate (IM-1), which loses a HCl moiety to produce an aldehyde (IM-2). The 
formed aldehyde can then be oxidized by an aldehyde dehydrogenase to produce TCEP-
M2, or reduced by an alcohol dehydrogenase to the corresponding alcohol (TCEP-M1) 
(Figure 5 and Table SI-3). Metabolic α-oxidation has been previously reported for 
halomethyl groups in other chemicals e.g. 1-chloropropane33 and was also suggested for 
TCEP in rats.31   
Phase II metabolism resulted in the formation of a glutathione conjugate of the parent 
compound TCEP (Figure 4). Identification of the glutathione conjugate was confirmed 
via LC-MS/MS analysis in neutral loss mode where the characteristic fractions of m/z = 
308 and 179 (neutral loss of 129) were observed in positive ion ESI mode (Figure SI-3). 
Moreover, the glucoronide conjugate of TCEP-M1 was also identified (Figure 4 and 
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Table SI-3). This conjugate was previously reported in rat and mice urine31 and 
suggested following in vitro exposure of rat and human liver preparations to TCEP.32   
3.4 TCIPP metabolic profile 
 Very little is known about the biotransformation of TCIPP. To the authors’ knowledge, 
there is only one recent paper studying the biotransformation of TCIPP by human liver 
microsomes and S9 fractions.13 In the current work, bis(1-chloro-2-propyl) hydrogen 
phosphate (BCIPP) was identified as a major metabolite by human HepG2 cells (Table 
3). Interestingly, two isomeric peaks were observed for BCIPP in samples exposed to 
the dust extract, while only one BCIPP peak was found in samples exposed to the 
standard mixture D2.  Van den Eede et al. reported two BCIPP isomers after incubating 
human liver microsomes with a TCIPP mixture of tris(1-chloro-2-propyl) phosphate 
(>66%) and tris(1-chloropropyl) phosphate (~30%). The formation of two BCIPP 
isomers was attributed to exposure of the microsomes to two TCIPP isomers.13 
Therefore, the detection of one BCIPP isomer following exposure of human HepG2 cells 
to D2, can be attributed to the presence of pure tris(1-chloro-2-propyl) phosphate in the 
Wellington® standard for TCIPP, which was used to prepare the dosing mixture D2 in 
this study.   
Furthermore, a hydroxylated metabolite, bis(1-chloro-2-propyl) hydroxy 2-propyl 
phosphate (TCEP-M1), and a carboxylic acid, bis(1-chloro-2-propyl) carboxy 2-ethyl 
phosphate (TCEP-M2), were also identified (Table 3). This suggests that α-oxidation 
(Figure 5) may constitute a major metabolic pathway for TCIPP in human hepatocytes. 
As a result of Phase II metabolism, the glutathione conjugate of TCIPP was identified 
(Table 3). However, no glucuronide or sulfate conjugates could be confirmed. 
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3.5 TDCIPP metabolic profile 
 Biotransformation of TDCIPP in indoor dust by human hepatocytes followed a similar 
profile to that observed for TCEP and TCIPP (Table 4). The diester, bis(1,3-dichloro-2-
propyl) hydrogen phosphate (BDCIPP), was the major metabolite formed after 24 hours 
of exposure (based on the relative peak area to that of the parent TDCIPP). This is in 
agreement with a previous in vivo study, which reported BDCIPP as the major urinary, 
fecal and biliary metabolite in rats following intravenous administration of radiolabeled 
TDCIPP.34 Another in vitro study also reported BDCIPP as the major metabolite of 
TDCIPP by human liver microsomes.13 In addition to the hydroxylated metabolite 
(TDCIPP-M1) and the carboxylic acid metabolite (TDCIPP-M2), the monoester, 1,3-
dichloro-2-propyl dihydrogen phosphate (DCIPP), was also identified (Table 4). Further 
hydrolysis of BDCIPP by esterases was previously suggested following in vitro 
incubation of TDCIPP with human liver microsomes.35 
The glutathione conjugate of TDCIPP was identified as a result of phase II metabolism 
(Table 4). This is in agreement with the results of previous in vitro studies using human 
liver microsomes.13,35 
4 Conclusion 
 A novel multi-residue analytical method was developed and applied to study the 
metabolic products formed when human HepG2 cell lines were challenged 
simultaneously – for the first time - with several widely-used organic flame retardants 
present in indoor dust. To mimic real-life exposure scenarios, human hepatocytes were 
concomitantly exposed for 24 hours to α-HBCD, β-HBCD, γ-HBCD, TCEP, TCIPP, and 
TDCIPP extracted from indoor dust. To identify the large number of metabolites formed, 
an ExactiveTM Plus OrbitrapTM high resolution mass spectrometer was applied following 
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chromatographic separation via UPLC. For the first time, target parent compounds were 
separated and monitored in a single run using an alternating positive and negative 
heated ESI source. Further metabolite separation and identification was performed 
using the high resolution (70,000 FWHM) accurate mass (up to 1 ppm) features of the 
OrbitrapTM-MS. Structural confirmation of the detected metabolites was achieved via all 
ion fragmentation (AIF) spectra using the optional higher collisional dissociation (HCD) 
cell of the MS. Hepatic metabolism of HBCDs in human was investigated for the first 
time. Several hydroxylated and debrominated phase I metabolites were identified, while  
conjugated phase II glucuronides of HBCDs were also confirmed. Hydroxylated, oxidized 
and conjugated metabolites of chlorinated phosphorous flame retardants were also 
observed and α-oxidation was proposed as a metabolic pathway for target PFRs in 
human hepatocytes.   
5 Supporting Information 
Further details on analytical method optimization, QA/QC measurements and structural 
confirmation of metabolites are provided as supporting information. 
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7 Tables 
 
Table 1: Optimized HESI-Orbitrap-MS parameters for analysis of target FRs. 
 
Parameter    Value 
Capillary temperature (°C) 300 
Source heater temperature (°C) 300 
Electrospray voltage (V) 4500 
Sheath gas flow (a.u.)* 15 
Auxiliary gas flow (a.u.)* 10 
S-lens frequency (Hz) 50 
Maximum injection time (ms) 80 
Automatic gain control (ions) 3 x 106 
HCG energy (ev) 35 
MS resolution (FWHM) 70000 
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Table 2: Metabolic profile of HBCDs by human HepG2 cell lines. 
Name Retention 
time 
(mins) 
Molecular 
formula 
Chemical structure Molecular 
ion [M-H]¯ 
Theoretical 
mass 
HBCD (3 
isomers) 
8.50, 8.69, 
8.84 
C12 H18 Br6 
 
640.6378 640.6369 
 
PBCD (2 
isomers) 
 
7.19, 7.58 
 
C12 H17 Br5 
 
 
560.6883 
 
560.7186 
TBCD 6.63 C12 H16 Br4 
 
478.7618 478.7866 
HBCD-
OH (5 
isomers) 
5.89, 6.09, 
6.38, 6.72, 
7.11 
C12 H18 Br6 
O 
 
656.6370 656.6318 
Di-
hydroxyl 
HBCD 
5.08 C12 H18 Br6 
O2 
 
672.6412 672.6346 
PBCD-
OH (2 
isomers) 
5.48, 5.71 C12H17 Br5 O 
 
574.7077 574.7805 
TBCD-
OH 
5.29 C12 H16 Br4 
O 
 
494.8342 494.7816 
HBCD-O-
Glu (2 
isomers) 
4.49, 4.68 C18 H26 Br6 
O7 
 
832.6766 832.6640 
PBCD-O-
Glu 
3.22 C18 H25 Br5 
O7 
 
750.7149 750.7398 
 
 
Page 21 of 30
ACS Paragon Plus Environment
Analytical Chemistry
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Table 3: Metabolic profile of TCIPP by human HepG2 cell lines. 
Name Retention 
time 
(mins) 
Molecular 
formula 
Chemical structure Molecular 
ion  
[M+H]+  
Theoretical 
mass 
TCIPP 5.58 C9H18Cl3O4P 
 
327.0081 327.0009 
BCIPP 1.86 C6 H13 Cl2 O4 
P 
 
250.9929 251.0002 
TCIPP-M1 3.81 C9 H19 Cl2 O5 
P 
 
309.0402 309.0348 
TCIPP-M2 3.55 C6 H12 Cl2 O6 
P 
 
322.9892 323.0140 
TCIPP-
Glutathione 
3.14 C19 H34 Cl2 
N3 O10 P S 
 
598.1295 598.1080 
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Table 4: Metabolic profile of TDCIPP by human HepG2 cell lines. 
Name Retention 
time 
(mins) 
Molecular 
formula 
Chemical structure Molecular 
ion [M+H]+  
Theoretical 
mass 
TDCIPP 6.52 C9 H15 Cl6 
O4 P 
 
430.8882 430.8809 
BDCIPP 2.87 C6 H11 Cl4 
O4 P 
 
320.9192 320.9120 
DCIPP 0.64 C3 H7 Cl2 O4 
P 
 
208.9533 208.9459 
TDCIPP-M1 4.22 C9 H16 Cl5 
O5 P 
 
412.9062 412.9149 
TDCIPP-M2 3.87 C9 H14 Cl5 
O6 P 
 
426.8787 426.8942 
TDCIPP-
Glutathione 
3.61 C19 H31 Cl5 
N3 
O10 P S 
 
702.0208 701.9982 
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8 Figures 1 
 2 
Figure 1: Chromatographic separation of HBCDs, TCEP, TCIPP and TDCIPP using alternating positive and negative ESI mode. 3 
 4 
 5 
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Figure 2: Full scan mass spectra of HBCD, PBCD, TBCD and their mono-hydroxylated metabolites. 6 
 7 
 8 
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Figure 3: Full scan mass spectra of HBCD and PBCD glucoronide conjugates. 9 
 10 
 11 
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Figure 4: UPLC-OrbitrapTM-MS selected ion chromatograms showing TCEP and its metabolites following incubation of indoor 12 
dust extract with human hepatocytes for 24 hours. 13 
 14 
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Figure 5: Schematic representation of α-oxidation proposed as a mechanism for biotransformation of TCEP by human 15 
hepatocytes. 16 
 17 
 18 
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